Association of Genetic Characteristics with Response to Venetoclax Plus Hypomethylating Agents in Relapsed and Refractory Acute Myeloid Leukemia

被引：2

作者：

Weng, Guangyang ^{[1
,2
]}

Zhang, Yu ^{[1
]}

Yu, Guopan ^{[1
]}

Xu, Na ^{[1
]}

Sun, Zhiqiang ^{[3
]}

Lin, Dongjun ^{[4
]}

Liang, Xinquan ^{[5
]}

Deng, Lan ^{[6
]}

Xiao, Jie ^{[7
]}

Zhang, Hongyu ^{[8
]}

Guo, Ziwen ^{[9
]}

Jin, Hua ^{[1
]}

Du, Xin ^{[10
]}

Liu, Qifa ^{[1
]}

机构：

[1] Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou, Peoples R China

[2] Shenzhen Univ, Peoples Hosp Shenzhen 2, Affiliated Hosp 1, Dept Hematol, Shenzhen, Peoples R China

[3] Southern Med Univ, Shenzhen Hosp, Dept Hematol, Shenzhen, Peoples R China

[4] Sun Yat Sen Univ, Affiliated Hosp 7, Dept Hematol, Shenzhen, Peoples R China

[5] First Peoples Hosp Chenzhou, Dept Hematol, Chenzhou, Peoples R China

[6] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Hematol, Shanghai, Peoples R China

[7] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Hematol, Guangzhou, Peoples R China

[8] Peking Univ, Dept Hematol, Shenzhen Hosp, Shenzhen, Peoples R China

[9] Zhongshan City Peoples Hosp, Dept Hematol, Zhongshan, Peoples R China

[10] Shenzhen Univ, Affiliated Hosp 1, Shenzhen Peoples Hosp 2, Dept Hematol, Shenzhen, Peoples R China

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-158762

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

下载

页码：2025 / 2026

页数：2

共 50 条

[1] Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia
Weng, Guangyang
Zhang, Yu
Yu, Guopan
Luo, Tingyue
Yu, Sijian
Xu, Na
Sun, Zhiqiang
Lin, Dongjun
Deng, Lan
Liang, Xinquan
Xiao, Jie
Zhang, Hongyu
Guo, Ziwen
Shao, Ruoyang
Du, Xin
Jin, Hua
Liu, Qifa
JOURNAL OF INTERNAL MEDICINE, 2023, 293 (03) : 329 - 339
[2] Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
Aldoss, Ibrahim
Yang, Dongyun
Pillai, Raju
Sanchez, James F.
Mei, Matthew
Aribi, Ahmed
Ali, Haris
Sandhu, Karamjeet
Al Malki, Monzr M.
Salhotra, Amandeep
Khaled, Samer
Sun, Weili
O'Donnell, Margaret
Snyder, David
Nakamura, Ryotaro
Stein, Anthony S.
Forman, Stephen J.
Marcucci, Guido
Pullarkat, Vinod
AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (10) : E253 - E255
[3] Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
Aldoss, Ibrahim
Yang, Dongyun
Aribi, Ahmed
Ali, Haris
Sandhu, Karamjeet
Al Malki, Monzr M.
Mei, Matthew
Salhotra, Amandeep
Khaled, Samer
Nakamura, Ryotaro
Snyder, David
O'Donnell, Margaret
Stein, Anthony S.
Forman, Stephen J.
Marcucci, Guido
Pullarkat, Vinod
HAEMATOLOGICA, 2018, 103 (09) : E404 - E407
[4] Venetoclax Plus Hypomethylating Agents for Relapsed/Refractory Acute Myeloid Leukemia (AML) Is Safe and Manageable in the Outpatient Setting
Nanni, Jacopo
Papayannidis, Cristina
Cristiano, Gianluca
Marconi, Giovanni
Sartor, Chiara
Parisi, Sarah
Ottaviani, Emanuela
Baldini, Lorenza
Testoni, Nicoletta
Baldazzi, Carmen
Ricci, Paolo
Bezzi, Chiara Di Giovanni
Abd-alatif, Rania
Paolini, Stefania
Cavo, Michele
Curti, Antonio
BLOOD, 2020, 136
[5] Venetoclax in Combination with Hypomethylating Agents Compared to Standard Chemotherapy in Relapsed/ Refractory Acute Myeloid Leukemia
Mohassel, Leila
Yakubi, Hanna
Jones, Kendra
Wang, Hongkun
Shafer, Danielle
BLOOD, 2022, 140 : 6158 - 6159
[6] Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
Tenold, Matthew E.
Moskoff, Benjamin N.
Benjamin, David J.
Hoeg, Rasmus T.
Rosenberg, Aaron S.
Abedi, Mehrdad
Tuscano, Joseph M.
Jonas, Brian A.
FRONTIERS IN ONCOLOGY, 2021, 11
[7] Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia
Graveno, Molly E.
Carulli, Alison
Freyer, Craig W.
Mangan, Brendan L.
Nietupski, Robert
Loren, Alison W.
Frey, Noelle, V
Porter, David L.
Gill, Saar, I
Hexner, Elizabeth O.
Luger, Selina M.
Martin, Mary Ellen
McCurdy, Shannon R.
Perl, Alexander E.
Babushok, Daria, V
Pratz, Keith W.
LEUKEMIA & LYMPHOMA, 2022, 63 (07) : 1645 - 1650
[8] Venetoclax plus Cladribine plus Low-Dose Cytarabine in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax plus Hypomethylating Agent
Steinauer, Nickolas
McCullough, Kristen
Al-Kali, Aref
Alkhateeb, Hassan
Begna, Kebede
Mangaonkar, Abhishek A.
Saliba, Antoine
Hefazi, Mehrdad
Litzow, Mark R.
Hogan, William J.
Shah, Mithun V.
Pardanani, Animesh D.
Badar, Talha
Murthy, Hemant S.
Foran, James M.
Yi, Cecilia Y. Arana
Tefferi, Ayalew
Gangat, Naseema
BLOOD, 2023, 142
[9] Influence of Molecular Abnormalities on Treatment Response of Venetoclax Plus Azacytidine and Homoharringtonine Versus Venetoclax Plus Hypomethylating Agent in Relapsed/Refractory Acute Myeloid Leukemia
Yu, Guopan
Yin, Zhao
Jin, Hua
Yu, Sijian
Li, Yuhua
Nie, Danian
Guo, Ziwen
Sun, Zhiqiang
Meng, Qingxiang
Zhao, Weihua
Lin, Dongjun
Xu, Na
Zhang, Yu
BLOOD, 2022, 140 : 11796 - 11796
[10] Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience
Angotzi, Francesco
Lessi, Federica
Leoncin, Matteo
Fili, Carla
Endri, Mauro
Lico, Albana
Visentin, Andrea
Pravato, Stefano
Candoni, Anna
Trentin, Livio
Gurrieri, Carmela
FRONTIERS IN ONCOLOGY, 2024, 14

← 1 2 3 4 5 →